237 related articles for article (PubMed ID: 16504510)
21. Clinical use of aromatase inhibitors in the treatment of advanced breast cancer.
Trunet PF; Vreeland F; Royce C; Chaudri HA; Cooper J; Bhatnagar AS
J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):241-5. PubMed ID: 9365196
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).
Lewis-Wambi JS; Jordan VC
Breast Dis; 2005-2006; 24():93-105. PubMed ID: 16917142
[TBL] [Abstract][Full Text] [Related]
23. Endocrine therapy for the treatment of postmenopausal women with breast cancer.
Harichand-Herdt S; Zelnak A; O'Regan R
Expert Rev Anticancer Ther; 2009 Feb; 9(2):187-98. PubMed ID: 19192957
[TBL] [Abstract][Full Text] [Related]
24. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
van de Velde CJ; Verma S; van Nes JG; Masterman C; Pritchard KI
Cancer Treat Rev; 2010 Feb; 36(1):54-62. PubMed ID: 19944537
[TBL] [Abstract][Full Text] [Related]
25. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
26. Advances in endocrine therapy for breast cancer: considering efficacy, safety, and quality of life.
Harwood KV
Clin J Oncol Nurs; 2004 Dec; 8(6):629-37. PubMed ID: 15637958
[TBL] [Abstract][Full Text] [Related]
27. Hormonal therapy for postmenopausal breast cancer: the science of sequencing.
Miller WR; Bartlett JM; Canney P; Verrill M
Breast Cancer Res Treat; 2007 Jun; 103(2):149-60. PubMed ID: 17039263
[TBL] [Abstract][Full Text] [Related]
28. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
Dunn BK; Ryan A
Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
[TBL] [Abstract][Full Text] [Related]
29. Are all aromatase inhibitors the same? A review of the current evidence.
Jänicke F
Breast; 2004 Dec; 13 Suppl 1():S10-8. PubMed ID: 15585378
[TBL] [Abstract][Full Text] [Related]
30. Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.
Carpenter R
Eur J Surg Oncol; 2008 Jul; 34(7):746-55. PubMed ID: 18296017
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant endocrine therapies for postmenopausal women with early breast cancer: standards and not.
Dellapasqua S; Castiglione-Gertsch M
Breast; 2005 Dec; 14(6):555-63. PubMed ID: 16188442
[TBL] [Abstract][Full Text] [Related]
32. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032.
Ingle JN; Suman VJ; Rowland KM; Mirchandani D; Bernath AM; Camoriano JK; Fishkin PA; Nikcevich DA; Perez EA;
J Clin Oncol; 2006 Mar; 24(7):1052-6. PubMed ID: 16505423
[TBL] [Abstract][Full Text] [Related]
33. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
Robertson JF; Osborne CK; Howell A; Jones SE; Mauriac L; Ellis M; Kleeberg UR; Come SE; Vergote I; Gertler S; Buzdar A; Webster A; Morris C
Cancer; 2003 Jul; 98(2):229-38. PubMed ID: 12872340
[TBL] [Abstract][Full Text] [Related]
34. Endocrine therapy of advanced disease: analysis and implications of the existing data.
Pritchard KI
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):460S-7S. PubMed ID: 12538501
[TBL] [Abstract][Full Text] [Related]
35. Optimising adjuvant endocrine treatment of breast cancer with aromatase inhibitors.
Fentiman IS
Int J Clin Pract; 2006 Jun; 60(6):689-93. PubMed ID: 16805754
[TBL] [Abstract][Full Text] [Related]
36. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
Mouridsen HT; Robert NJ
Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
[TBL] [Abstract][Full Text] [Related]
37. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
Gradishar W
Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
[TBL] [Abstract][Full Text] [Related]
38. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
[TBL] [Abstract][Full Text] [Related]
39. Aromatase inhibitors in the management of early breast cancer.
Nabholtz JM
Eur J Surg Oncol; 2008 Nov; 34(11):1199-207. PubMed ID: 18359182
[TBL] [Abstract][Full Text] [Related]
40. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
